Evidence map›Paper›PMID 23801799›Full record

ArticleDiabetes care2013

A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass.

Glenn S Gerhard, Amanda M Styer, G Craig Wood, Stephen L Roesch, Anthony T Petrick, Jon Gabrielsen, William E Strodel, Christopher D Still, George Argyropoulos

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 6 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 6 syntheses or guidelines pooled it, 219 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Glenn S GerhardWeis Center for Research, Geisinger Clinic, Danville, Pennsylvania, USA.
Amanda M Styer
G Craig Wood
Stephen L Roesch
Anthony T Petrick
Jon Gabrielsen
William E Strodel
Christopher D Still
George Argyropoulos
Geisinger Medical Center · US

Funding

Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D, TAYLOR, SIMEON I. · 2005 to 2019
$17.3M
Genetic determinants of NAFLD severity and progressionR01DK091601 · NIDDK · TRANSLATIONAL GENOMICS RESEARCH INST · PI DISTEFANO, JOHANNA K, GERHARD, GLENN S · 2011 to 2015
$2.9M
Genetic Determinants of Weight Loss and Resolution of Co-MorbiditiesR01DK088231 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI GERHARD, GLENN S · 2011 to 2015
$2.5M
NIDDK NIH HHS DK-072488NIDDK NIH HHS DK-088231NIDDK NIH HHS DK-091601NIDDK NIH HHS P30 DK072488NIDDK NIH HHS R01 DK088231NIDDK NIH HHS R01 DK091601
6 · The paper itself

Abstract

objectiveRoux-en-Y gastric bypass (RYGB) in humans can remit type 2 diabetes, but the operative mechanism is not completely understood. In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. In this study, we tested the hypothesis that the FGF19-BA pathway plays a role in the remission of human diabetes after RYGB surgery. RESEARCH DESIGN AND

methodsCohorts of diabetic and nondiabetic individuals of various body weights were used. In addition, RYGB patients without diabetes (No-Diabetes), RYGB patients with diabetes who experienced remission for at least 12 months after surgery (Diabetes-R), and RYGB patients with diabetes who did not go into remission after surgery (Diabetes-NoR) were studied. Circulating FGF19 and BA levels, hepatic glycogen content, and expression levels of genes regulating the FGF19-BA pathway were compared among these groups of patients using pre- and postoperative serum samples and intraoperative liver biopsies.

resultsPreoperatively, patients with diabetes had lower FGF19 and higher BA levels than nondiabetic patients, irrespective of body weight. In diabetic patients undergoing RYGB, lower FGF19 levels were significantly correlated with increased hepatic expression of the cholesterol 7alpha-hydroxylase 1 (CYP7A1) gene, which modulates BA production. Following RYGB surgery, however, FGF19 and BA levels (particularly cholic and deoxycholic acids) exhibited larger increases in Diabetic-R patients compared with nondiabetic and Diabetic-NoR patients.

conclusionsTaken together, the baseline and postoperative data implicate the FGF19-CYP7A1-BA pathway in the etiology and remission of type 2 diabetes following RYGB surgery.

Indexed as

AgedBile Acids and SaltsCholesterol 7-alpha-HydroxylaseDiabetes Mellitus, Type 2FemaleFibroblast Growth FactorsGastric BypassHumansMaleMiddle AgedBile Acids and SaltsCholesterol 7-alpha-HydroxylaseCYP7A1 protein, humanFGF19 protein, humanFibroblast Growth Factors

Identifiers

PMID23801799
PMCPMC3687273
OpenAlexW2156356963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.